Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. Bone Health and Bone-targeted Therapies for Prostate Cancer

Bone Health and Bone-targeted Therapies for Prostate Cancer Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03148 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Bone Health and Bone-Targeted Therapies (...) for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline , MD 1 x Philip J. Saylor ; , MSc 2 x R. Bryan Rumble ; , MD, MS 3 x Scott Tagawa ; , MD 4 x James A. Eastham ; , MD, MSc 5 x Antonio Finelli ; , MD 6 x Pavan S. Reddy ; , MBA 7 x Terry M. Kungel ; , JD 8 x Merel G. Nissenberg ; and , MBA, MD 9 x Jeff M. Michalski 1 Massachusetts General Hospital, Boston, MA 2 American Society of Clinical Oncology, Alexandria, VA 3 Weill Cornell Medicine, New York, NY 4 Memorial Sloan Kettering Cancer

2020 American Society of Clinical Oncology Guidelines

2. Optimum Imaging Strategies for Advanced Prostate Cancer

Optimum Imaging Strategies for Advanced Prostate Cancer Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02757 Journal of Clinical Oncology - published online before print January 15, 2020 PMID: Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline , MD 1 x Edouard J (...) , Atlanta, GA 24 Hartford Hospital, Hartford, CT E.J.T. and H.A.V. were Expert Panel co-chairs. Abstract Section: PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened

2020 American Society of Clinical Oncology Guidelines

3. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer CUAJ • February 2020 • Volume 14, Issue 2 © 2020 Canadian Urological Association CUA gUideline 17 Cite as: Can Urol Assoc J 2020;14(2):17-23. http://dx.doi.org/10.5489/cuaj.6384 Published online December 5, 2019 Introduction Metastatic prostate cancer remains an incurable disease. In Canada, approximately 8% of men with prostate cancer are diagnosed (...) de novo with metastatic disease and, in 2018, roughly 1200 men were diagnosed with de novo metastat- ic prostate cancer (PC). 1 The mainstay of treatment for de novo metastatic PC is androgen-deprivation therapy (ADT), which is initially effective in almost all patients. Progression is inevitable, however, heralded by a rise in prostate-specific antigen (PSA), increasing disease burden, and/or worsening symptoms — a disease state called metastatic castration- resistant prostate cancer (mCRPC

2020 Canadian Urological Association

4. Molecular Biomarkers in Localized Prostate Cancer

Molecular Biomarkers in Localized Prostate Cancer Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02768 Journal of Clinical Oncology - published online before print December 12, 2019 PMID: Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline , MD 1 x Scott E. Eggener ; , MSc 2 (...) . were Expert Panel co-chairs. Abstract Section: PURPOSE This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging. METHODS An ASCO multidisciplinary Expert Panel

2020 American Society of Clinical Oncology Guidelines

5. Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC)

Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC) Published 10 February 2020 Statement of advice SMC2268 apalutamide 60mg film-coated tablets (Erleada®) Janssen-Cilag Ltd 10 January 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation apalutamide (Erleada®) is not recommended for use within NHSScotland. Indication under review: In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC

2020 Scottish Medicines Consortium

6. Salvage reirradiation using external beam radiotherapy for local failure in prostate cancer: a systematic review and meta-analysis

Salvage reirradiation using external beam radiotherapy for local failure in prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2020 PROSPERO

7. EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging

EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging [ 18 F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0 | SpringerLink Advertisement Search Search SpringerLink Search [ 18 F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0 , , , , , , , , , , , & ( 2019 ) 251 Accesses 4 Altmetric Abstract The aim of this guideline is to provide standards (...) for the recommendation, performance, interpretation, and reporting of [ 18 F]Fluciclovine PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of [ 18 F]Fluciclovine PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice. This is a preview of subscription content, to check access. Access options 2. Washburn LC, Sun TT, Byrd B, Hayes RL, Butler TA. 1-aminocyclobutane[11C] carboxylic

2020 Society of Nuclear Medicine and Molecular Imaging

8. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy (...) -Sensitive Prostate Cancer , , , , , , , , , Affiliations Expand Affiliations 1 University of Wisconsin, Madison, WI. 2 University of California, San Francisco, San Francisco, CA. 3 Johns Hopkins University, Baltimore, MD. PMID: 31644357 DOI: Item in Clipboard Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Douglas G McNeel et al. J Clin Oncol . 2019 Show details J Clin Oncol Actions

2020 EvidenceUpdates

9. Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer

Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer 1 Published 13 January 2020 1 SMC2215 abiraterone acetate 500mg film-coated tablets (Zytiga®) Janssen-Cilag Ltd 6 December 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following (...) a full submission assessed under the orphan medicine process abiraterone acetate (Zytiga ® ) is accepted for use within NHSScotland. Indication under review: abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy. Abiraterone acetate in combination with prednisone and androgen deprivation therapy demonstrated superiority over androgen deprivation

2020 Scottish Medicines Consortium

10. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer (Epub draft)

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer (Epub draft) CUAJ – CUA Guideline So et al Guideline: mCNPC & mCSPC Canadian Urological Association-Canadian Urologic Oncology Group guideline on Metastatic castration-naive and castration-sensitive prostate cancer Alan So 1 ; Kim Chi 2 ; Brita Danielson 3 ; Neil Fleshner 4 ; Anil Kapoor 5 ; Tamim Niazi 6 ; Frederic Pouliot 7 ; Ricardo Rendon 8 (...) Montréal, Montreal, QC, Canada Cite as: Can Urol Assoc J 2019 December 5; Epub ahead of print. http://dx.doi.org/10.5489/cuaj.6384 Published online December 5, 2019 *** Introduction Metastatic prostate cancer remains an incurable disease. In Canada, approximately 8% of men with prostate cancer are diagnosed de novo with metastatic disease, and, in 2018, roughly 1200 men were diagnosed with de novo metastatic prostate cancer (PC) (1). The mainstay of treatment for de novo metastatic PC is androgen

2020 Canadian Urological Association

11. Efficacy and toxicity of carbon ion therapy or proton therapy for prostate cancer: a systematic review and meta-analysis

Efficacy and toxicity of carbon ion therapy or proton therapy for prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

12. Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostate cancer: a systematic review and meta-analysis

Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

13. Comparison of PET/CT and MRI in the diagnosis of bone metastases in patients with prostate cancer: a network meta-analysis

Comparison of PET/CT and MRI in the diagnosis of bone metastases in patients with prostate cancer: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

14. Comparison of different PSMA PET/CT radio tracers in prostate cancer patients with biochemical failure after primary treatment: a systematic review and meta-analysis

Comparison of different PSMA PET/CT radio tracers in prostate cancer patients with biochemical failure after primary treatment: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

15. A systematic review of guidelines and clinical practice recommendations for genetic screening, prostate cancer screening, genetic counselling and the treatment of prostate cancer in men with DNA damage response gene (DDR+ ) mutations

A systematic review of guidelines and clinical practice recommendations for genetic screening, prostate cancer screening, genetic counselling and the treatment of prostate cancer in men with DNA damage response gene (DDR+ ) mutations Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission

2020 PROSPERO

16. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial (Abstract)

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the greatest benefit from the addition of platinum. We aimed to determine whether adding carboplatin to cabazitaxel (...) would improve the outcomes of men with metastatic castration-resistant prostate cancer.We did a phase 1-2, open label, randomised study at two centres in men with progressive metastatic castration-resistant prostate cancer. In phase 1, patients received intravenous cabazitaxel 20-25 mg/m2 and intravenous carboplatin area under the curve (AUC) 3-4 mg/mL per min every 21 days. The maximum tolerated dose was defined as the highest dose cohort studied in which one of six or fewer patients experienced

2019 EvidenceUpdates

17. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study (Abstract)

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study Numerous pretreatment risk classification tools are available for prostate cancer. Which tool is best in predicting prostate cancer death is unclear.To systematically compare the prognostic performance of the most commonly used pretreatment risk stratification tools for prostate cancer.A nationwide cohort study was conducted, including 154 811 men (...) in Prostate Cancer data Base Sweden (PCBaSe) 4.0 diagnosed with nonmetastatic prostate cancer during 1998-2016 and followed through 2016.We compared the D'Amico, National Institute for Health and Care Excellence (NICE), European Association of Urology (EAU), Genito-Urinary Radiation Oncologists of Canada (GUROC), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), and Cambridge Prognostic Groups (CPG) risk group systems; the Cancer of the Prostate Risk Assessment (CAPRA

2019 EvidenceUpdates

18. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Apalutamide (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-09 Apalutamide (...) (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-09 Version 1.0 Apalutamide (prostate cancer)) 24 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Apalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 24 January 2019 Internal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study (Abstract)

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. We aimed to assess health-related quality of life (...) (HRQOL) in TITAN, including pain and fatigue.In this randomised, placebo-controlled, double-blind, phase 3 study, patients with metastatic castration-sensitive prostate cancer (defined as not receiving ADT at the time of metastatic disease progression) aged 18 years and older, receiving continuous ADT (selected at the investigator's discretion), and with an Eastern Cooperative Oncology Group performance status score of 0 or 1 were randomly assigned (1:1), using an interactive web response system

2019 EvidenceUpdates

20. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Eur Urol Actions 2019 Oct 31 [Online ahead of print] Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

2019 EvidenceUpdates